PE20030907A1 - Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa - Google Patents

Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa

Info

Publication number
PE20030907A1
PE20030907A1 PE2003000205A PE2003000205A PE20030907A1 PE 20030907 A1 PE20030907 A1 PE 20030907A1 PE 2003000205 A PE2003000205 A PE 2003000205A PE 2003000205 A PE2003000205 A PE 2003000205A PE 20030907 A1 PE20030907 A1 PE 20030907A1
Authority
PE
Peru
Prior art keywords
alkyl
formyl
amino
transferase
methyl
Prior art date
Application number
PE2003000205A
Other languages
English (en)
Inventor
Laura Anne Bloom
Theodore James Boritzki
Leslie Ann Kuhn
Luke Raymond Zhender
Jerry Jialum Meng
Richard Charles Ogden
Donald James Skalitzky
Pei-Pei Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030907A1 publication Critical patent/PE20030907A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

SE REFIERE A UN METODO PARA DESTRUIR CELULAS DEFICIENTES EN METILTIOADENOSINA-FOSFORILASA (MTAP) QUE COMPRENDE ADMINISTRAR a)INHIBIDOR DE GLICINAMIDA-RIBONUCLEOTIDO-FORMILTRANSFERASA, AMINOIMIDAZOLCARBOXIMIDA-RIBONUCLEOTIDO-FORMILTRANSFERASA DE FORMULA A (ACIDO N-(5-[2-(2-AMINO-4(3H)-OXO-5,6,7,8-TETRAHIDROPIRIDO[2,3-d]-PIRIMIDIN-6-IL)-(R)-ETIL]-4-METILTIENO-2-IL)-L-GLUTAMICO, O UN COMPUESTO OXOPIRIDO DE FORMULA II; A ES S, Se; GRUPO ES UN INTERCALADOR NO CICLICO; ANILLO ES CICLOALQUILO, HETEROCICLOALQUILO, ARILO, HETEROARILO; R1 Y R2 SON H, ALQUILO, GRUPO HIDROLIZABLE; R3 ES H, ALQUILO, CICLOALQUILO; b)UN AGENTE ANTITOXICO (ANALOGO DE METILADENOSINA FOSFORILASA) EN UNA CANTIDAD PARA INCREMENTAR LA DOSIS TOLERADA MAXIMA DEL INHIBIDOR DE FORMULA X; DONDE R41 ES Rg, RgYRhRi, CONRjRk, COORh; Rg ES ALQUILO, ALQUENILENO, ALQUINILENO; Y ES O, NH, S, METILENO; Rh, Ri SON H, ALQUILO, ALQUENILO, ALQUINILO; Rj Y Rk SON H, ALQUILO, AMINO, HALOALQUILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS (2S,3R,4R,5R)-5-(6-AMINO-9H-PURIN-9-IL)-4-(METILTIO)-2-[(METIL-TIO)METIL]TETRAHIDROFURAN-3-OL; (2S,3S,4R,5R)-2-(6-AMINO-9H-PURIN-9-IL)-5-{[(4-CLOROBENCIL)TIO]-METIL}-TETRAHIDROFURAN-3,4-DIOL, ENTRE OTROS
PE2003000205A 2002-03-04 2003-02-28 Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa PE20030907A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36164502P 2002-03-04 2002-03-04
US43227502P 2002-12-09 2002-12-09

Publications (1)

Publication Number Publication Date
PE20030907A1 true PE20030907A1 (es) 2003-10-29

Family

ID=27791683

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000205A PE20030907A1 (es) 2002-03-04 2003-02-28 Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa

Country Status (14)

Country Link
US (1) US20040043959A1 (es)
EP (1) EP1482977A1 (es)
KR (1) KR20040091089A (es)
AR (1) AR038863A1 (es)
AU (1) AU2003206019A1 (es)
BR (1) BR0308222A (es)
CA (1) CA2477422A1 (es)
IL (1) IL163776A0 (es)
NO (1) NO20044191L (es)
PA (1) PA8568201A1 (es)
PE (1) PE20030907A1 (es)
TW (1) TW200304380A (es)
UY (1) UY27692A1 (es)
WO (1) WO2003074083A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113328A1 (en) * 2003-06-25 2004-12-29 Pfizer Inc. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a garft inhibitor
JP2005292087A (ja) * 2004-04-05 2005-10-20 Shionogi & Co Ltd ５’−デオキシ−５’−メチルチオアデノシンに対する抗体
US7981902B2 (en) * 2006-06-28 2011-07-19 Duquesne University Of The Holy Ghost Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with FR type receptors
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP5789252B2 (ja) * 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US9725479B2 (en) * 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
AU2011336415B2 (en) 2010-12-03 2016-08-11 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
WO2012075500A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MA39986A (fr) 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JPWO2016056606A1 (ja) * 2014-10-07 2017-07-20 国立大学法人京都大学 ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
EA201892031A1 (ru) 2016-03-10 2019-02-28 Янссен Фармацевтика Нв Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5
CN108884108B (zh) * 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7054681B2 (ja) 2016-06-24 2022-04-14 インフィニティー ファーマシューティカルズ， インコーポレイテッド 組合せ療法
MX2019002962A (es) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Inhibidores espirobiciclicos de la interaccion de menina-mll.
BR112019004764A2 (pt) 2016-09-14 2019-05-28 Janssen Pharmaceutica Nv inibidores bicíclicos fundidos da interação menina-mll
MX2019003843A (es) * 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
EP3555103B1 (en) 2016-12-15 2021-09-22 Janssen Pharmaceutica NV Azepane inhibitors of menin-mll interaction
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
CA3084449A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN109111445B (zh) * 2018-11-02 2020-12-18 哈尔滨商业大学 5’-呋喃甲酰酯-3’-脱氧腺苷的合成方法及应用
CN109369758B (zh) * 2018-11-02 2021-04-13 哈尔滨商业大学 5′-(6-氯烟酰酯)-3′-脱氧腺苷的合成方法及其应用
EP3939988A4 (en) * 2019-03-20 2022-08-24 Korea Research Institute of Chemical Technology PHARMACEUTICAL COMPOSITION WITH NOVEL HETEROCYCLIC AZOLOPYRIMIDINE COMPOUND AS THE ACTIVE SUBSTANCE
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
WO2020249663A1 (en) 2019-06-12 2020-12-17 Janssen Pharmaceutica Nv Novel spirobicyclic intermediates
WO2021254529A1 (zh) * 2020-07-14 2021-12-23 江苏先声药业有限公司 双环类化合物
LV15670B (lv) * 2021-03-10 2023-11-20 Latvijas Organiskās Sintēzes Institūts Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori
EP4326273A1 (en) * 2021-04-19 2024-02-28 Emory University Quinazoline derivatives, pharmaceutical compositions, and therapeutic uses related to nox inhibition
CN113603721B (zh) * 2021-06-21 2023-12-01 重庆文理学院 一种合成saicar的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
US5945427A (en) * 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
JPH08504765A (ja) * 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換５−チアピリミジノンおよび５−セレノピリミジノン化合物
DK0681584T3 (da) * 1993-01-29 2001-08-27 Agouron Pharma Kondenserede, heterocykliske glutaminsyrederivater som antiproliferative midler
US5594139A (en) * 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5840505A (en) * 1993-12-29 1998-11-24 The Regents Of The University Of California Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells
US5942393A (en) * 1993-12-29 1999-08-24 The Regents Of The University Of California Method for the detection of the presence or absence of methylthioadenosine phosphorylase (MTASE) in a cell sample by detection of the presence or absence of MTASE encoding nucleic acid in the cell sample
JP3473956B2 (ja) * 1994-07-28 2003-12-08 アグーロン ファーマシューティカルズ，インコーポレーテッド 抗増殖剤およびｇａｒｆｔ阻害剤として有用な化合物
US5608082A (en) * 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors

Also Published As

Publication number Publication date
US20040043959A1 (en) 2004-03-04
NO20044191L (no) 2004-09-30
CA2477422A1 (en) 2003-09-12
UY27692A1 (es) 2003-10-31
WO2003074083A1 (en) 2003-09-12
EP1482977A1 (en) 2004-12-08
AR038863A1 (es) 2005-02-02
KR20040091089A (ko) 2004-10-27
BR0308222A (pt) 2005-02-09
IL163776A0 (en) 2005-12-18
AU2003206019A1 (en) 2003-09-16
PA8568201A1 (es) 2003-11-12
TW200304380A (en) 2003-10-01

Similar Documents

Publication Publication Date Title
PE20030907A1 (es) Terapias de combinacion para tratar celulas deficientes en metiltioadenosina-fosforilasa
PE131699A1 (es) Inhibidores de aminotiazol de cinasas dependientes de ciclina
BR9509686A (pt) Biaribultírico saturado ou ácidos 5-biaripentanóicos e derivados como inibidores de matrizes metaloproteases
PE20010482A1 (es) Derivados de 3-ureido-pirazol y procedimiento para su preparacion
US20050222222A1 (en) Pyrrolidine compounds
RU2004130426A (ru) Циклические амиды
AR065389A2 (es) Composicion farmaceutica para disminuir la hiperglucemia y para profilaxis y tratamiento de la diabetes
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
RU2015119640A (ru) Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
HRP20140737T1 (hr) Inhibitori hepatitis c virusa
HRP20120706T1 (hr) Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
PE20041079A1 (es) Acetil-2-hidroxi-1,3-diaminoalcanos
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
CA2485850A1 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EA200702238A1 (ru) Комбинация, способ и композиция для лечения рака
JO2239B1 (en) Method for preparing benzothophen derivatives
AR029145A1 (es) Compuesto de hidroxamato pirrolidina sustituida, inhibidores de metaloproteasa, composicion farmaceutica que lo comprende y uso para elaborar una composicion farmaceutica
PT97631A (pt) Processo de preparacao de compostos inibidores de renina,incluindo (2s)-2-benzil-3-(1-metilpiperazin-4-ilsufonil)propionil-(l)-(4-tiazolil)-ala-amida de ( 2r,3r,4s)-2-amino-1-ciclo-hexil-3,4-di-hidroxi-6-metil-heptano e seus analogos, e de composicoes farmaceuticas
PE20020759A1 (es) Derivados de bencilamina con base prolina como inhibidores de trombina
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal